Clinical Trials Logo

Methadone clinical trials

View clinical trials related to Methadone.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06086171 Recruiting - Hip Fractures Clinical Trials

Perioperative Methadone Compared to Placebo in Elderly Hip Fracture Patients

Start date: November 10, 2023
Phase: Phase 4
Study type: Interventional

Hip fractures are associated with severe pain and are sustained by the elderly population. Demand for adequate pain relief combined with a low tolerance for analgesic drugs makes the treatment of elderly hip fracture patients difficult. Perioperative methadone could improve the analgesic treatment of these patients. An earlier pilot study showed that 0.10 mg/kg was safe to use. This study further investigates the advantages of methadone. The study's objective is to investigate the analgesic effects of a single dose of methadone given during hip fracture surgery.

NCT ID: NCT05459402 Recruiting - Chronic Pain Clinical Trials

Divided or Single Exposure (DOSE) Study

Start date: February 21, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate whether once versus twice daily dosing of methadone will be an effective method for managing comorbid pain and opioid use disorder.

NCT ID: NCT04764825 Recruiting - Pain, Postoperative Clinical Trials

Methadone for Spinal Fusion Surgery.

METASPINE
Start date: February 26, 2021
Phase: Phase 4
Study type: Interventional

A prospective double-blind, randomized controlled trial investigating the effect of a single-dose of intraoperative methadone in patients undergoing spinal fusion.

NCT ID: NCT04480554 Recruiting - Inflammation Clinical Trials

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

AMOHI-1
Start date: January 30, 2023
Phase: Phase 2
Study type: Interventional

HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut. The overall objective of this study is to define the impact of long-term mu-opiate receptor stimulation or blockage with medication for opiate use disorder (i.e, methadone, buprenorphine/naloxone, or extended-release naltrexone) on the kinetics and extent of immune reconstitution on HIV-1 infected people who inject opiate and initiating antiretroviral therapy.